Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MRTTSE:6034 -1.38%59 10-Year ROIIC % is -1.58 as of Dec. 2025. GuruFocus rates TSE:6034 with a GF Score™ of 59/100 and a GF Value™ of 円618.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 484 Healthcare Providers & Services companies, MRT ranks worse than 65.5% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
MRT's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was -1.58%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for MRT's 10-Year ROIIC % or its related term are showing as below:
TSE:6034's 10-Year ROIIC % is ranked worse than 65.5% of 484
companies
in the Healthcare Providers & Services industry
Industry Median: 3.4
vs TSE:6034: -1.58
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
MRT 10-Year ROIIC % Related Terms
MRT 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for MRT's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6034 vs HCA, THC, DVA: 10-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, MRT's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRT 10-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRT's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where MRT's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
MRT (TSE:6034) has a 10-Year ROIIC % of -1.58 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on MRT and its competitors. According to the industry distribution chart, MRT ranks #317 out of 484 companies in the Healthcare Providers & Services industry, placing it in the top 65.5%.
Is MRT's 10-Year ROIIC % too high?
MRT's current 10-Year ROIIC % is -1.58. Based on the distribution chart, MRT ranks #317 out of 484 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MRT has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MRT's 10-Year ROIIC % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MRT ranks #317 out of 484 companies for 10-Year ROIIC %. This places MRT in the lower half of its industry. The industry median 10-Year ROIIC % is 3.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Healthcare Providers & Services company?
The median 10-Year ROIIC % among Healthcare Providers & Services companies is 3.40, based on 484 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on MRT and its competitors. For the Healthcare Providers & Services industry, the median 10-Year ROIIC % is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MRT's current 10-Year ROIIC % is -1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRT stock overvalued right now?
Based on GuruFocus' analysis, MRT (TSE:6034) is currently considered Fairly Valued. The stock's GF Value™ is 円618.17, compared to a current price of 円641.00 — trading 3.7% above its estimated fair value. The current 10-Year ROIIC % is -1.58. MRT's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For MRT (TSE:6034), the current 10-Year ROIIC % is -1.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRT (TSE:6034) Overvalued in 2026?
Based on GuruFocus' analysis, MRT stock appears to be overvalued.
The current stock price of 円641.00 is trading 3.7% above its estimated GF Value™ of 円618.17.
GuruFocus considers MRT to be Fairly Valued.
Key valuation signals for TSE:6034:
10-Year ROIIC %: -1.58
GF Value™: 円618.17 vs. price of 円641.00 (3.7% above fair value)
No single metric tells the full story. See the TSE:6034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRT Inc engages in the business of medical personnel placement services through the Internet. It provides part-time and full-time physician referral services through the physician referral site, as well as part-time job referral, job change introduction services to nurses, pharmacists, clinical laboratory technicians, clinical engineers, and radiologists. Further, the company engages in the research and development of analytical and analytical methods for various biological samples, such as microorganisms, blood, proteins, and genes; and research and development, manufacture, and sale of medical and medical examination equipment, and analytical instruments.
59GF Score
Get the complete analysis for TSE:6034
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6034 has been successfully added to your 
